3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Rectal Neoplasms
12
Colonic Neoplasms
12
Neoplasm Metastasis
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Gallbladder Neoplasms
3
Colorectal Cancer Metastatic
3
Cholangiocarcinoma
3
Neutropenia
2
Neoplasms
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Recurrence
1
Pretreated Metastatic Colorectal Cancer
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gastric Adenocarcinoma
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
trifluridine tipiracil drug combination
×
Clear all
NCT05476796
2024-10-24
LOGICAN
UNICANCER
Phase 2
Recruiting
118 enrolled